6 mins to read F&P’s stock stages a relief rally after investor fears allayed The dual-listed medical device company has delivered strong revenue and product growth for 2026 despite US tariffs and the Middle East conflict. F&P has shifted around production volumes to lessen US tariff impacts. Fiona Rotherham Tue, 26 May 2026 © All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription. Dual-listed medical device company Fisher & Paykel Healthcare has delivered strong revenue
and profit growth for 2026 despite headwinds from the Middle East conflict and US tariffs. There had been a sell-off of the stock prior to the results announcement with fears of a downgrade in its FY27 Want to read more? It’s easy. Choose your subscription Already have an account? Login Smartphone Only Subscription NZ$29.95 / monthly Monthly Premium Online Subscription NZ$49.95 / monthly Smartphone Only Annual Subscription NZ$299.00 / yearly Yearly Premium Online Subscription NZ$499.00 / yearly Premium Group Membership 10 Users NZ$385+GST / monthly
$38.5 per user – Pay by monthly credit card debit Premium Group Membership 20 Users NZ$660+GST / monthly $33 per user – Pay by monthly credit card debit Premium Group Membership 50 Users NZ$1375+GST / monthly $27.5 per user – Pay by monthly credit card debit Premium Group Membership 100 Users NZ$2100+GST / monthly $21 per user – Pay by monthly credit card debit Yearly Premium Online Subscription + NBR Marketplace NZ$999.00 / yearly Individual Group membership NBR Marketplace Exclusive FREE offer for uni students
studying at a New Zealand university (valued at $499). View terms and conditions. Fiona Rotherham Tue, 26 May 2026 Contact the Writer: fiona@nbr.co.nz News tip? Question? Typo? Let us know: editor@nbr.co.nz © All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription. Fisher & Paykel Healthcare Lewis Gradon healthcare US tariffs Middle East war Investment Free News Alerts Sign up to get the latest stories and insights delivered to your inbox – free, every day. Company
profile Powered by: Previous Close Avg Daily Volume Daily High 52 Week High 52 Week Low Related News Investors wait for ailing CSL to recover Investment The man behind the masks: F&P Healthcare’s Lewis Gradon Investment F&P Healthcare surpasses $1b 1H revenue for the first time F&P Healthcare investors murmur not shout over pay incentive bump Investment F&P Healthcare to be hit with $11m US tariff impact in FY26
Fisher & Paykel Healthcare, F&P, stock rally, US tariffs, Middle East conflict, FY27 downgrade, revenue growth, profit growth, production volumes